Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin
| Autor: | Charlotte T. Hansen, Mae Sheikh-Ali, Louis Chaykin, Thor S. S. Nielsen, Mark Warren, Paul Norwood, Serge Jabbour |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Insulin degludec
medicine.medical_specialty Insulin glargine business.industry Endocrinology Diabetes and Metabolism Urology 030209 endocrinology & metabolism Type 2 diabetes Hypoglycemia medicine.disease Feature Articles Crossover study 03 medical and health sciences High dose insulin 0302 clinical medicine Endocrinology Internal medicine Internal Medicine medicine In patient 030212 general & internal medicine business medicine.drug Glycemic |
| Zdroj: | Clinical Diabetes : A Publication of the American Diabetes Association |
| ISSN: | 1945-4953 0891-8929 |
| Popis: | IN BRIEF Many patients with type 2 diabetes require high basal insulin doses, necessitating multiple injections, increasing patient burden, and resulting in reduced treatment adherence. This randomized, controlled, crossover trial compared the efficacy, safety, and patient-reported outcomes for a concentrated formulation of insulin degludec (200 units/mL) to those of insulin glargine in patients requiring high doses of basal insulin. By offering equivalent glycemic control while reducing the rate of confirmed hypoglycemia and the number of injections required for administration, insulin degludec 200 units/mL may be preferred by patients with type 2 diabetes who require high basal insulin doses. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|